Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial

Preclinical observations that killing of chronic lymphocytic leukemia (CLL) cells was dexamethasone (DEX) were enhanced by concomitant inhibition of Bruton’s tyrosine kinase and janus kinases (JAKs) motivated a phase II trial to determine if clinical responses to ibrutinib could be deepened by DEX a...

Descripción completa

Detalles Bibliográficos
Autores principales: Spaner, David E., Luo, Yuxuan, Wang, Guizhei, Gallagher, Jennifer, Tsui, Hubert, Shi, Yonghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683523/
https://www.ncbi.nlm.nih.gov/pubmed/34791813
http://dx.doi.org/10.1002/cam4.4378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683523/
https://www.ncbi.nlm.nih.gov/pubmed/34791813
http://dx.doi.org/10.1002/cam4.4378

Ejemplares similares